John Fletcher

John founded Fletcher Spaght in 1983 and remains active as the Managing Director Emeritus. FSI has been unique in applying analytic rigor coupled with operational expertise to a broad range of clients, portfolio companies and the investment community. John has particular interests in devices, specifically in cardiology, cardiac surgery, and orthopedics, as well as in biopharma and healthcare IT. 

Prior to founding Fletcher Spaght, John was a Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.

John currently serves as the Chairman of the Board of Directors for ClearPoint Neuro, Koru Medical, Metabolon and Optinose. Previously, he served as Chairman of Spectranetics during its turnaround and subsequent sale to Philips N.V. For this work as well as his work on the board of Axcelis Corporation, he was selected as Director of the Year by the National Association of Corporate Directors. He is Chairman Emeritus of the Corporate Collaboration Council at the Thayer School of Engineering/Tuck School of Business at Dartmouth College and serves on the Board of Advisors of Beth Israel Deaconess Medical Center and the Whitehead Institute at MIT.

John received his MBA from Southern Illinois University, a Master’s degree in International Finance from Central Michigan University, and a BBA in Marketing from George Washington University. He was an Instructor for courses in international business and a PhD Candidate at the Wharton School of the University of Pennsylvania. He served as a Captain and jet pilot in the U.S. Air Force and continues to be active in aviation.